Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb adaptive crossover PSG study of MK-6096 in primary insomnia
2009-015773-12Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filorexant in Insomnia (2 arms), sponsored by Merck & Co. Primary endpoints: Sleep efficiency at Night 1 and Sleep efficiency at end of 4 weeks. Started Oct 2009; status: completed.
02
Drugs
filorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on 2009-015773-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015773-12.